18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The inflammasome generates caspase-1 p20/p10, presumed to be the active protease. Boucher et al. demonstrate that the inflammasome contains an active caspase-1 species, p33/p10, and functions as a holoenzyme. Further caspase-1 self-processing generates and releases p20/p10 to terminate protease activity.

          Abstract

          Host-protective caspase-1 activity must be tightly regulated to prevent pathology, but mechanisms controlling the duration of cellular caspase-1 activity are unknown. Caspase-1 is activated on inflammasomes, signaling platforms that facilitate caspase-1 dimerization and autoprocessing. Previous studies with recombinant protein identified a caspase-1 tetramer composed of two p20 and two p10 subunits (p20/p10) as an active species. In this study, we report that in the cell, the dominant species of active caspase-1 dimers elicited by inflammasomes are in fact full-length p46 and a transient species, p33/p10. Further p33/p10 autoprocessing occurs with kinetics specified by inflammasome size and cell type, and this releases p20/p10 from the inflammasome, whereupon the tetramer becomes unstable in cells and protease activity is terminated. The inflammasome–caspase-1 complex thus functions as a holoenzyme that directs the location of caspase-1 activity but also incorporates an intrinsic self-limiting mechanism that ensures timely caspase-1 deactivation. This intrinsic mechanism of inflammasome signal shutdown offers a molecular basis for the transient nature, and coordinated timing, of inflammasome-dependent inflammatory responses.

          Graphical Abstract

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

          Interleukin-1 beta (IL-1 beta)-converting enzyme cleaves the IL-1 beta precursor to mature IL-1 beta, an important mediator of inflammation. The identification of the enzyme as a unique cysteine protease and the design of potent peptide aldehyde inhibitors are described. Purification and cloning of the complementary DNA indicates that IL-1 beta-converting enzyme is composed of two nonidentical subunits that are derived from a single proenzyme, possibly by autoproteolysis. Selective inhibition of the enzyme in human blood monocytes blocks production of mature IL-1 beta, indicating that it is a potential therapeutic target.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme.

            The interleukin-1 beta (IL-1 beta) converting enzyme (ICE) processes the inactive IL-1 beta precursor to the proinflammatory cytokine. Adherent monocytes from mice harboring a disrupted ICE gene (ICE-/-) did not export IL-1 beta or interleukin-1 alpha (IL-1 alpha) after stimulation with lipopolysaccharide. Export of tumor necrosis factor-alpha and interleukin-6 (IL-6) from these cells was also diminished. Thymocytes from ICE-/- mice were sensitive to apoptosis induced by dexamethasone or ionizing radiation, but were resistant to apoptosis induced by Fas antibody. Despite this defect in apoptosis, ICE-/- mice proceed normally through development.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The neutrophil NLRC4 inflammasome selectively promotes IL-1β maturation without pyroptosis during acute Salmonella challenge.

              The macrophage NLRC4 inflammasome drives potent innate immune responses against Salmonella by eliciting caspase-1-dependent proinflammatory cytokine production (e.g., interleukin-1β [IL-1β]) and pyroptotic cell death. However, the potential contribution of other cell types to inflammasome-mediated host defense against Salmonella was unclear. Here, we demonstrate that neutrophils, typically viewed as cellular targets of IL-1β, themselves activate the NLRC4 inflammasome during acute Salmonella infection and are a major cell compartment for IL-1β production during acute peritoneal challenge in vivo. Importantly, unlike macrophages, neutrophils do not undergo pyroptosis upon NLRC4 inflammasome activation. The resistance of neutrophils to pyroptotic death is unique among inflammasome-signaling cells so far described and allows neutrophils to sustain IL-1β production at a site of infection without compromising the crucial inflammasome-independent antimicrobial effector functions that would be lost if neutrophils rapidly lysed upon caspase-1 activation. Inflammasome pathway modification in neutrophils thus maximizes host proinflammatory and antimicrobial responses during pathogen challenge.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                jem
                The Journal of Experimental Medicine
                Rockefeller University Press
                0022-1007
                1540-9538
                05 March 2018
                : 215
                : 3
                : 827-840
                Affiliations
                [1 ]Centre for Inflammation and Disease Research, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia
                [2 ]School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia
                [3 ]Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA, Australia
                [4 ]The Kennedy Institute of Rheumatology, University of Oxford, Oxford, England, UK
                Author notes
                Correspondence to Kate Schroder: k.schroder@ 123456imb.uq.edu.au
                [*]

                M. Monteleone, R.C. Coll, and K.W. Chen contributed equally to this paper.

                Author information
                http://orcid.org/0000-0003-0075-8893
                http://orcid.org/0000-0002-7359-6023
                http://orcid.org/0000-0002-6270-8413
                http://orcid.org/0000-0002-8171-4763
                http://orcid.org/0000-0001-9261-3805
                Article
                20172222
                10.1084/jem.20172222
                5839769
                29432122
                b8bc175e-7105-42c3-9ef9-b39e50ff64bc
                © 2018 Boucher et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 05 December 2017
                : 01 January 2018
                : 02 January 2018
                Funding
                Funded by: Australian Research Council, DOI http://doi.org/10.13039/501100000923;
                Award ID: DP160102702
                Funded by: Fonds de Recherche du Québec - Santé, DOI http://doi.org/10.13039/501100000156;
                Funded by: University of Queensland, DOI http://doi.org/10.13039/501100001794;
                Funded by: University of Queensland, DOI http://doi.org/10.13039/501100001794;
                Funded by: National Health and Medical Research Council, DOI http://doi.org/10.13039/501100000925;
                Award ID: 1059729
                Funded by: Australian Research Council, DOI http://doi.org/10.13039/501100000923;
                Award ID: FT130100361
                Funded by: National Health and Medical Research Council, DOI http://doi.org/10.13039/501100000925;
                Award ID: 1141131
                Funded by: Australian Cancer Research Foundation, DOI http://doi.org/10.13039/501100000947;
                Categories
                Research Articles
                Article
                311

                Medicine
                Medicine

                Comments

                Comment on this article